4-(1H-indol-3-yl)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide | 1443248-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1H-indol-3-yl)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide
• 英文别名: 4-(1H-indol-3-yl)-N-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide
• CAS: 1443248-77-8
• 化学式: C₂₂H₂₄N₄O₂
• 分子量: 376.458
• InChiKey: ZRWMYSXRVAEPFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  77.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲哚 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 28.5h， 生成 4-(1H-indol-3-yl)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs

  摘要：

  A new series of urea-based, 4-bicyclic heteroaryl-piperidine derivatives as potent SCD1 inhibitors is described. The structure-activity relationships focused on bicyclic heteroarenes and aminothiazole-urea portions are discussed. A trend of dose-dependent decrease in body weight gain in diet-induced obese (DIO) mice is also demonstrated. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.096

文献信息

• [EN] SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINYL-CARBOXAMIDE SUBSTITUÉ UTILES EN TANT QU'INHIBITEURS DE SCD 1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2013085954A1

  公开（公告）日：2013-06-13

  The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-羧酰胺衍生物、含有它们的制药组合物以及它们作为SCD1抑制剂的用途，适用于治疗肥胖症、2型糖尿病和其他相关代谢性疾病。
• SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140364393A1

  公开（公告）日：2014-12-11

  The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-羧酰胺衍生物、包含它们的制药组合物以及它们作为SCD1抑制剂的用途，用于治疗肥胖症、2型糖尿病和其他相关代谢性疾病。
• US9238658B2
  申请人：——

  公开号：US9238658B2

  公开（公告）日：2016-01-19
• 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs
  作者：Shyh-Ming Yang、Yuting Tang、Rui Zhang、Huajun Lu、Gee-Hong Kuo、Michael D. Gaul、Yaxin Li、George Ho、James G. Conway、Yin Liang、James M. Lenhard、Keith T. Demarest、William V. Murray

  DOI：10.1016/j.bmcl.2013.09.096

  日期：2013.12

  A new series of urea-based, 4-bicyclic heteroaryl-piperidine derivatives as potent SCD1 inhibitors is described. The structure-activity relationships focused on bicyclic heteroarenes and aminothiazole-urea portions are discussed. A trend of dose-dependent decrease in body weight gain in diet-induced obese (DIO) mice is also demonstrated. (C) 2013 Elsevier Ltd. All rights reserved.